menu
    • menu
    [{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Chugai Pharma Europe","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Netupitant","moa":"||NK-1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Chugai Pharma Europe","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Chugai Pharma Europe"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Esteve Quimica","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Netupitant","moa":"||NK-1 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Esteve Quimica","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Esteve Quimica"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ BridgeBio Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Juniper Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Juniper Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Juniper Biologics"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Xediton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"FGFR3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Xediton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Xediton Pharmaceuticals"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Immedica Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Immedica Pharma"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Netupitant","moa":"||5-HT3 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Angelini Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Nimesulide","moa":"Undisclosed","graph1":"Neurology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helsinn Advanced Synthesis \/ Angelini Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Angelini Pharma"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Anamorelin HCl","moa":"GHS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Helsinn Advanced Synthesis \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Oberland Capital Management"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vepafestinib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vepafestinib","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mechlorethamine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Mechlorethamine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"Helsinn Advanced Synthesis \/ Kyowa Kirin","highestDevelopmentStatusID":"15","companyTruncated":"Helsinn Advanced Synthesis \/ Kyowa Kirin"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pracinostat","moa":"||Pan-HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Helsinn Advanced Synthesis \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HM06","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Helsinn Advanced Synthesis \/ Taiho Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Helsinn Advanced Synthesis

    Menu

    Helsinn Advanced Synthesis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Dexamethasone,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Esteve Quimica

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Helsinn Group & ESTEVE Renew Partnership for AKYNZEO® and ALOXI® in Germany

                            Details : The agreement aims for the commercialization of Akynzeo (combination of netupitant-palonosetron) and Aloxi (palonosetron) for the treatment of chemotherapy-induced nausea and vomiting in adults.

                            Product Name : Akynzeo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : Netupitant,Dexamethasone,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Esteve Quimica

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Dexamethasone,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Chugai Pharma Europe

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Helsinn, Chugai renew partnership to sell AKYNZEO® in UK and Ireland

                            Details : The agreement aims to commercialise Akynzeo (combination of netupitant-palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients, in UK and Ireland.

                            Product Name : Akynzeo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 06, 2024

                            Lead Product(s) : Netupitant,Dexamethasone,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Chugai Pharma Europe

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Dexamethasone,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Helsinn Group launches Akynzeo injection in US market

                            Details : Akynzeo (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting.

                            Product Name : Akynzeo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 26, 2024

                            Lead Product(s) : Netupitant,Dexamethasone,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nimesulide

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Angelini Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Helsinn and Angelini Renew Partnership for AULIN® and MESULID® in Central Europe

                            Details : Through the agreement, Angelini Pharma will focus on commercializing Mesulid (nimesulide) in Europe. It is indicated for treating patients suffering from acute pain.

                            Product Name : Mesulid

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 24, 2024

                            Lead Product(s) : Nimesulide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Angelini Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anamorelin HCl

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Oberland Capital Management

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Helsinn Closes Financing Agreement with Oberland Capital

                            Details : Adlumiz (anamorelin) is a selective, novel, orally active ghrelin receptor agonist. Upon binding to its receptor, ghrelin stimulates multiple pathways in the positive regulation of body weight, muscle mass, appetite and metabolism.

                            Product Name : Adlumiz

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 01, 2023

                            Lead Product(s) : Anamorelin HCl

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Oberland Capital Management

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Helsinn Publishes Results From A Secondary Analysis Of A Phase 3 Trial In Patients With CINV Helsinn Publishes...

                            Details : AKYNZEO (Netupitant) is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin based highly emetogenic chemotherapy and moderately em...

                            Product Name : Akynzeo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 01, 2023

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Helsinn Announces Publication of New Data Evaluating Impact Of NEPA (netupitant/palonosetron) On Hospital Cost...

                            Details : Akynzeo is a combination of netupitant, a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors and palonosetron, a 5-HT3 receptor antagonist with a strong binding affinity for this receptor. It is indicated for nausea due to cancer che...

                            Product Name : Akynzeo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 02, 2023

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Immedica Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Helsinn and Immedica Enter Exclusive Partnership for Commercialisation of Cancer Supportive Care Products in C...

                            Details : Akynzeo (netupitant) is a 5-HT3 and NK1 receptor antagonist fixed combination approved in Europe in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based highly emetogenic chemotherapy and moderately emetogeni...

                            Product Name : Akynzeo

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 24, 2023

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Immedica Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Helsinn Announces Presentation On CINV Trial at European Society for Medical Oncology (ESMO) Asia

                            Details : Akynzeo is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy.

                            Product Name : Akynzeo

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 29, 2022

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Helsinn To Present Data at Upcoming AMMF's 2022 European Cholangiocarcinoma Conference

                            Details : Truseltiq (Infigratinib) is a potent orally administered, selective, ATP‐competitive, kinase inhibitor of FGFRs, with highest affinity for FGFR 1, 2, and 3, is indicated for treatment of adults with previously treated metastatic cholangiocarcinoma with...

                            Product Name : Truseltiq

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 05, 2022

                            Lead Product(s) : Infigratinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth